Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bicyclic fused pyrazole derivatives for the treatment of rsv

A compound, -NR0 technology, applied in the fields of microorganisms, biochemical equipment and methods, antibody medical components, etc., can solve the problems of unmet, high cost, preventing large-scale implementation, etc.

Active Publication Date: 2019-04-02
GEORGIA STATE UNIV RES FOUND INC
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Adoption of the humanized neutralizing antibody palivizumab for immunoprophylaxis in high-risk pediatric patients, but high cost prevents large-scale implementation
[0013] Therefore, there is still an urgent unmet need for new compounds that can be used to treat and prevent RSV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bicyclic fused pyrazole derivatives for the treatment of rsv
  • Bicyclic fused pyrazole derivatives for the treatment of rsv
  • Bicyclic fused pyrazole derivatives for the treatment of rsv

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0194] The method preparation of series A compound

[0195] In all experimental data reported below, the following abbreviations are used:

[0196] rt: room temperature

[0197] UV: Ultraviolet

[0198] HPLC: High Pressure Liquid Chromatography

[0199] Rt: retention time

[0200] LCMS: Liquid Chromatography Mass Spectrometry

[0201] NMR: nuclear magnetic resonance spectroscopy

[0202] CC: column chromatography

[0203] TLC: Thin Layer Chromatography

[0204] sat: saturated

[0205] aq: water-based

[0206] DCM: dichloromethane

[0207] DCE: dichloroethane

[0208] DMF: Dimethylformamide

[0209] DIPEA: Diisopropylethylamine

[0210] EtOAc: ethyl acetate

[0211] TEA: Triethylamine

[0212] THF: Tetrahydrofuran

[0213] TFA: Trifluoroacetic acid

[0214] t-BuOK: potassium tert-butoxide

[0215] n-BuOH: n-Butanol

[0216] EtOH: ethanol

[0217] HOAc: acetic acid

[0218] o / n: Overnight

[0219] MW: microwave

[0220] h: hours

[0221] min: minute

[02...

Embodiment 1A

[0224] Embodiment 1A: conventional synthesis method A1

[0225]

[0226] Exemplary Experimental Procedure for General Method A1

[0227] 1.4-(3-(cyclopentyloxy)-4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-b]pyridine-6(7H )-ketone (AVG-065) was synthesized as follows:

[0228]

[0229] Compound M2 (200mg, 1.3mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione (272mg, 1.9mmol) and 3-(cyclopentyloxy)-4- A mixture of methoxybenzaldehyde (415 mg, 1.9 mmol) in EtOH (10 mL) was refluxed for 16 h. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was diluted with water and extracted with EtOAc (30 mL x 2). The organic layer was washed with water and brine, washed with Na 2 SO 4 Drying, filtration and concentration afforded crude product, which was purified by preparative TLC to afford compound AVG-065 (50 mg, 10% yield) as a white solid.

[0230]Agilent LCMS1200-6110, column: Waters X-Bridge C18 (50mm*4.6mm*3.5μm); column temperature: 4...

Embodiment 1B

[0239] Embodiment 1B: conventional synthesis method A2

[0240]

[0241] Exemplary Experimental Procedure for General Method A2

[0242] 1. Synthesis of 3-(2-(2,4-dimethoxybenzylidene)hydrazino)propionitrile (F2-2)

[0243]

[0244] Hydrazine hydrate (80%, 5.0 g, 124 mmol) was added to a stirred solution of acrylonitrile (6.0 g, 113 mmol) in THF (50 mL) cooled to 0 °C over a period of about 20 min, then the reaction mixture was stirred at room temperature 2h. To the reaction mixture was added 2,4-dimethoxybenzaldehyde (19.7 g, 119 mmol) over a period of about 15 min, and the reaction mixture was stirred at room temperature for 4 h. Subsequent concentration gave a crude oil which was used directly in the next step.

[0245] Agilent LCMS1200-6110, column: Waters X-Bridge C18 (50mm*4.6mm*3.5μm); column temperature: 40°C; flow rate: 2.0mL / min; mobile phase: within 1.6min from 95% [water+0.05% TFA] and 5% [CH 3 CN+0.05%TFA] to 0%[Water+0.05%TFA] and 100%[CH 3 CN+0.05%TF...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 359,894, filed July 8, 2016, and U.S. Provisional Application No. 62 / 333,992, filed May 10, 2016, the disclosures of which are incorporated herein in their entirety . [0003] Statement Regarding Federal Funding for Research and Development [0004] This invention was made with government support under grants HD079327 and AI071002 awarded by the National Institutes of Health (NIH). The government has certain rights in this invention. technical field [0005] The present invention relates to small molecule therapeutic agents for the treatment of respiratory syncytial virus (RSV) and related members of the family Pneumoviridae and Paramyxoviridae (such as human metapneumovirus, mumps virus, human parainfluenza virus and Nipah and Hender pull virus). Background technique [0006] Respiratory syncytial virus (RSV) is a member of the Paramyxoviri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/155C07K14/135
CPCA61K31/437A61K31/444C12N2760/18511A61P31/12C07D471/04C07D519/00
Inventor 理查德·K·普莱佩尔艾迪·李约翰·维纳乔艾丽丝·布尔克
Owner GEORGIA STATE UNIV RES FOUND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com